Ipsen: agreement for the acquisition of Epizyme


(CercleFinance.com) – Ipsen announces that it has entered into a definitive agreement to acquire Epizyme, a biopharmaceutical company ‘committed to developing and delivering innovative treatments through new epigenetic drugs for cancer patients’.

The acquisition focuses on Epizyme’s lead drug, Tazverik (tazemetostat), a first-in-class, non-chemotherapy EZH2 inhibitor approved by U.S. authorities under a fast-track process in 2020.

Ipsen will initiate a takeover bid for the outstanding shares of Epizyme at a price of $1.45 per share in cash at the closing of the transaction, for an initial total amount estimated at $247 million, to which is added a certificate of value guarantee (CVG) per share.

The transaction, unanimously approved by the respective boards of directors of Ipsen and Epizyme, is expected to close by the end of the third quarter of 2022, subject to the satisfaction of all closing conditions.

Copyright © 2022 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.


Twitter


Facebook


LinkedIn


E-mail





Source link -85